Dropulic Boro, June Carl H
Lentigen, Baltimore, MD 21227, USA.
Hum Gene Ther. 2006 Jun;17(6):577-88. doi: 10.1089/hum.2006.17.577.
More than 40 million people are infected with human immunodeficiency virus (HIV), and a successful vaccine is at least a decade away. Although highly active antiretroviral therapy prolongs life, the maintenance of viral latency requires life-long treatment and results in cumulative toxicities and viral escape mutants. Gene therapy offers the promise to cure or prevent progressive HIV infection by interfering with HIV replication and CD4+ cell decline long term in the absence of chronic chemotherapy, and approximately 2 million HIV-infected individuals live in settings where there is sufficient infrastructure to support its application with current technology. Although the development of HIV/AIDS gene therapy has been slow, progress in a number of areas is evident, so that studies to date have significantly advanced the field of gene-based immunotherapy. Advances have helped to define a series of ongoing and planned trials that may shed light on potential mechanisms for the successful clinical gene therapy of HIV.
超过4000万人感染了人类免疫缺陷病毒（HIV），而成功的疫苗至少还需要十年时间才能研发出来。尽管高效抗逆转录病毒疗法延长了患者的生命，但病毒潜伏状态的维持需要终身治疗，并且会导致累积毒性和病毒逃逸突变体。基因疗法有望在无需长期化疗的情况下，通过长期干扰HIV复制和CD4+细胞减少来治愈或预防进行性HIV感染，并且大约有200万HIV感染者生活在有足够基础设施来支持当前技术应用的地区。尽管HIV/AIDS基因疗法的发展一直很缓慢，但在许多领域都取得了明显进展，因此迄今为止的研究显著推动了基于基因的免疫疗法领域的发展。这些进展有助于确定一系列正在进行和计划中的试验，这些试验可能会揭示HIV成功临床基因治疗的潜在机制。
